2004
Iodine 125 Versus Palladium 103 Implants for Prostate Cancer
Peschel RE, Colberg JW, Chen Z, Nath R, Wilson LD. Iodine 125 Versus Palladium 103 Implants for Prostate Cancer. The Cancer Journal 2004, 10: 170-174. PMID: 15285926, DOI: 10.1097/00130404-200405000-00006.Peer-Reviewed Original ResearchConceptsExternal beam radiation therapyMinimum tumor doseDisease-free survival ratesComplication rateTumor doseProstate cancerRadiation therapyClinical outcomesPrognostic groupsBiochemical disease-free survival ratesSurvival rateBiochemical disease-free survivalDisease-free survivalHigh complication ratePoor prognostic groupProstate-specific antigenHormonal therapyT stageGleason scoreSingle institutionTransperineal implantationFavorable groupGrade 3Treatment groupsPatients
1999
Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103
Peschel R, Chen Z, Roberts K, Nath R. Long‐term complications with prostate implants: Iodine‐125 vs. palladium‐103. International Journal Of Cancer 1999, 7: 278-288. PMID: 10580897, DOI: 10.1002/(sici)1520-6823(1999)7:5<278::aid-roi3>3.0.co;2-3.Peer-Reviewed Original ResearchMeSH KeywordsActuarial AnalysisBrachytherapyCell DeathFollow-Up StudiesForecastingHumansIodine RadioisotopesLongitudinal StudiesMaleModels, BiologicalNeoplasm StagingPalladiumProbabilityProstatic NeoplasmsRadioisotopesRadiopharmaceuticalsRadiotherapy DosageRelative Biological EffectivenessRetrospective StudiesTreatment OutcomeConceptsLong-term complicationsMinimum tumor dosesComplication ratePd-103Lower overall complication ratePalladium-103Long-term complication rateIodine-125Overall complication rateHigh complication rateProstate cancer patientsProstate implantsActuarial probabilityGrade IIILog10 cell killCancer patientsVs. 6Tumor dosesClinical practiceCell killProstate cancer brachytherapyEffective doseNormal tissuesPatientsTissue beds